scholarly journals Usefulness of GDF-15 concentrations in plasma in prognosing serious adverse events and bleeding in acute pulmonary embolism: a prospective observational study

2020 ◽  
Author(s):  
Marta Skowrońska ◽  
Martyna Skrzyńska ◽  
Michał Machowski ◽  
Zbigniew Bartoszewicz ◽  
Marzanna Paczyńska ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Adverse Events ◽  
Observational Study ◽  
Acute Pulmonary Embolism ◽  
Prospective Observational Study ◽  
Serious Adverse Events

scholarly journals D-dimer-to-platelet Ratio as a Novel Marker of in-hospital Adverse Outcomes Among Patients With Acute Pulmonary Embolism: a Single-center Retrospective Study

2021 ◽  
Author(s):  
Xincheng Li ◽  
Yaowu He ◽  
Yu Shang ◽  
Yi Yang ◽  
Menghan Wang ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Retrospective Study ◽  
Adverse Events ◽  
Medical Records ◽  
Acute Pulmonary Embolism ◽  
Multivariate Analyses ◽  
Adverse Outcomes ◽  
Therapeutic Interventions ◽  
Serious Adverse Events ◽  
D Dimer

Abstract Background: This retrospective study aimed to evaluate the value of D-dimer to platelets ratio (DPR) in predicting the in-hospital prognosis of patients with acute pulmonary embolism (APE).Methods: We retrospectively reviewed the medical records of 237 patients with APE admitted from January 2016 to August 2020. The associations between the DPR and other predictors and serious adverse events were analyzed with univariate and multivariate analyses.Results: A total of 134 (56.5%) patients were categorized into the low DPR group (DPR <4.55) and 103 (43.5%) in the high DPR group (DPR ≥4.55) according to the cut-off value for the DPR of 4.55 with a sensitivity of 87.5% and a specificity of 62.0%, respectively. The model that included DPR revealed a significant improvement in the accuracy of the predictive value compared with the sPESI score alone (AUC: 0.721 [95% CI: 0.636-0.807]; P <0.001 vs AUC: 0.607 [95% CI: 0.496-0.718]; P=0.085; respectively. Multivariate analysis showed that DPR (P=0.001) and the pulmonary embolus position (P=0.011) were independent factors of serious adverse events (SAEs) of APE inpatients. The in-hospital SAEs rate was significantly higher in the high DPR group compared with the low DPR group.Conclusion: Our findings showed that DPR is seemed to be a novel marker of risk stratification in patients with APE. This parameter may be used to identify these patients at higher risk for clinical adverse events, and individualization of therapeutic interventions should be timely considered.

scholarly journals Fragmented QRS Complex Predicts In-Hospital Adverse Events and Long-Term Mortality in Patients with Acute Pulmonary Embolism

2015 ◽  
Vol 21 (5) ◽  
pp. 470-478 ◽  
Author(s):  
Mehmet Serkan Cetin ◽  
Elif Hande Ozcan Cetin ◽  
Fazil Arisoy ◽  
Mevlüt Serdar Kuyumcu ◽  
Serkan Topaloglu ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Adverse Events ◽  
Acute Pulmonary Embolism ◽  
Qrs Complex ◽  
Fragmented Qrs ◽  
Long Term Mortality

scholarly journals Premedication practices for tracheal intubation in neonates transported by French medical transport teams: a prospective observational study

BMJ Open ◽  
2019 ◽  
Vol 9 (11) ◽  
pp. e034052 ◽  
Author(s):  
Ricardo Carbajal ◽  
Noella Lode ◽  
Azzedine Ayachi ◽  
Ourida Chouakri ◽  
Véronique Henry-Larzul ◽  
...  
Keyword(s):  
Adverse Events ◽  
Observational Study ◽  
Prospective Observational Study ◽  
Drug Regimen ◽  
Muscle Rigidity ◽  
Neonatal Transport ◽  
Registration Number ◽  
Medical Transport ◽  
The Mean ◽  
Paris Region

ObjectivesPremedication practices for neonatal tracheal intubations have not yet been described for neonatal transport teams. Our objective is to describe the use of sedation/analgesia (SA) for tracheal intubations and to assess its tolerance in neonates transported by medical transport teams in France.SettingThis prospective observational study was part of the EPIPPAIN 2 project and collected around-the-clock data on SA practices in neonates intubated by all five paediatric medical transport teams of the Paris region during a 2-month period. Intubations were classified as emergent, semiemergent and non-emergent. Sedation level and conditions of intubation were assessed with the Tonus, Reactivity, Awareness and Conditions of intubation to Help in Endotracheal intubation Assessment (TRACHEA score). The scores range from 0 to 10 representing an increasing ladder from adequate to inadequate sedation, and from excellent to very poor conditions of intubation.Participants40 neonates intubated in 28 different centres.ResultsThe mean (SD) age was 34.9 (3.9) weeks, and 62.5% were intubated in the delivery room. 30/40 (75%) of intubations were performed with the use of SA. In 18/30 (60.0%) intubations performed with SA, the drug regimen was the association of sufentanil and midazolam. Atropine was given in 19/40 intubations. From the 16, 21 and 3 intubations classified as emergent, semiemergent and non-emergent, respectively, 8 (50%), 19 (90.5%) and 3 (100%) were performed with SA premedication. 79.3% of intubations performed with SA had TRACHEA scores of 3 or less. 22/40 (55%) infants had at least one of the following adverse events: muscle rigidity, bradycardia below 100/min, desaturation below 80% and nose or pharynx–larynx bleeding. 7/24 (29.2%) of those who had only one attempt presented at least one of these adverse events compared with 15/16 (93.8%) of those who needed two or more attempts (p<0.001).ConclusionSA premedication is largely feasible for tracheal intubations performed in neonates transported by medical transport teams including intubations judged as emergent or semiemergent.Trial registration numberNCT01346813; Results.

scholarly journals Efficacy and safety of eltrombopag in the treatment of severe chronic immune thrombocytopenia in children of China: A single-center observational study

2019 ◽  
Vol 33 ◽  
pp. 205873841987212 ◽  
Author(s):  
Xiaoling Cheng ◽  
Kuo Yan ◽  
Jingyao Ma ◽  
Zhenping Chen ◽  
Libo Zhao ◽  
...  
Keyword(s):  
Adverse Events ◽  
Observational Study ◽  
Immune Thrombocytopenia ◽  
Response Rates ◽  
Drug Dosage ◽  
Efficacy And Safety ◽  
Bleeding Events ◽  
Serious Adverse Events ◽  
Durable Response ◽  
Chronic Immune Thrombocytopenia

The treatment of severe chronic immune thrombocytopenia (SCITP) in pediatric patients is challenging. We evaluated the clinical efficacy and safety of eltrombopag in children with SCITP in China. This observational study was carried out at the Hematology Oncology Center, Beijing Children’s Hospital between April 2017 and July 2018. Patients with SCITP who had at least 12 weeks of eltrombopag treatment and follow-up data were included. Baseline data, such as age, drug dosage, pre-study platelet count, concomitant medications, and bleeding severity, were collected. Treatment response rates, durable response rates, bleeding events, and adverse events were assessed during eltrombopag therapy for at least 12 weeks. The median duration of eltrombopag therapy was 16 (12–48) weeks. The overall, complete, and partial response rates were 75% (15/20), 35% (7/20), and 40% (8/20), respectively. The durable response rate was 70% (14/20). No serious bleeding events or serious adverse events occurred during the study period. Eltrombopag appears to be effective and safe in children with SCITP, although additional research is needed to confirm this.

scholarly journals Impact of persistent anaemia on mortality in patients hospitalised with acute pulmonary embolism: an Australian retrospective observational study

BMJ Open ◽  
2019 ◽  
Vol 9 (4) ◽  
pp. e027112
Author(s):  
Wallace Chow ◽  
Christopher Wong ◽  
Jerrett K Lau ◽  
Vincent Chow ◽  
Leonard Kritharides ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Observational Study ◽  
Acute Pulmonary Embolism ◽  
Retrospective Observational Study ◽  
Study Cohort ◽  
Prognostic Impact ◽  
Tertiary Referral Centre ◽  
Baseline Haemoglobin ◽  
The Impact ◽  
Acute Pe

ObjectivesAnaemia is associated with increased mortality in acute pulmonary embolism (PE) patients. However, prior studies have not examined the prognostic impact of trends in plasma haemoglobin during admission. This study investigates the impact of changes in haemoglobin level on mortality during hospital stay in acute PE.Study designA retrospective observational study.SettingTertiary-referral centre in Australia.ParticipantsConsecutive patients from 2000 to 2012 admitted with confirmed acute PE were identified from a dedicated PE database. Haemoglobin levels on days 1, 3–4, 5–6 and 7 of admission were retrieved. Patients without both baseline haemoglobin and subsequent haemoglobin levels were excluded (n=327), leaving 1099 patients as the study cohort. Anaemia was defined as haemoglobin <130 g/L for men and <120 g/L for women. There were 576 patients without anaemia throughout admission, 65 with transient anaemia (anaemic on day 1, but subsequently normalised during admission), 122 with acquired anaemia (normal on day 1 but developed anaemia during admission) and 336 with persistent anaemia. A total of 71 patients received blood transfusion during admission.Main outcome measure6-month mortality was tracked from a state-wide death database and analysed using multivariable modelling.ResultsAfter adjusting for transfusion, patietns with persistent anaemia had a significantly increased 6-month mortality risk (adjusted HR 1.97, 95% CI 1.26 to 3.09, p=0.003) compared with patients without anaemia. There was no difference in mortality between patients with transient or acquired anaemia and patients without anaemia.ConclusionAmong patients who had anaemia during their admission for acute PE, only the subgroup with persistent anaemia demonstrated worse outcomes.

scholarly journals Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Klemens Budde ◽  
Thomas Rath ◽  
Volker Kliem
Keyword(s):  
Adverse Events ◽  
Observational Study ◽  
Kidney Transplant ◽  
Prospective Observational Study ◽  
Erythropoietin Receptor ◽  
Study Entry ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Receptor Activator ◽  
Continuous Erythropoietin Receptor Activator

In a multicenter, prospective, observational study of 279 kidney transplant recipients with anemia, the efficacy and safety of once-monthly continuous erythropoietin receptor activator (C.E.R.A.) were assessed to a maximum of 15 months. The main efficacy variable was the proportion of patients achieving a hemoglobin level of 11-12 g/dL at each of visits between months 7 and 9. At study entry, 224 patients (80.3%) were receiving erythropoiesis stimulating agent (ESA) therapy including darbepoetin alfa (98), epoetin beta (61), and C.E.R.A. (45). The mean (SD) time between C.E.R.A. applications was 34.0 (11.9) days. Among 193 patients for whom efficacy data were available, mean (SD) hemoglobin was 11.1 (0.99) g/dL at study entry, 11.5 (1.1) g/dL at month 7, 11.6 (1.3) g/dL at month 9, and 11.4 (1.1) g/dL at month 15. During months 7–9, 20.7% of patients had all hemoglobin values within the range 11-12 g/dL and 64.8% were within 10–13 g/dL. Seven patients (2.5%) discontinued C.E.R.A. due to adverse events or serious adverse events. In this observational trial under real-life conditions, once-monthly C.E.R.A. therapy achieved stable hemoglobin levels in stable kidney transplant recipients with good tolerability, and with no requirement for any dose change in 43% of patients.

Sign in / Sign up

Export Citation Format

Share Document